Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H11N2O3.Na |
Molecular Weight | 254.2171 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCC1(C(=O)NC(=O)[N-]C1=O)C2=CC=CC=C2
InChI
InChIKey=WRLGYAWRGXKSKG-UHFFFAOYSA-M
InChI=1S/C12H12N2O3.Na/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16;/h3-7H,2H2,1H3,(H2,13,14,15,16,17);/q;+1/p-1
DescriptionSources: https://www.drugs.com/monograph/phenobarbital.htmlCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01174
Sources: https://www.drugs.com/monograph/phenobarbital.html
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01174
Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16981722 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LUMINAL Approved UseShort-term treatment of insomnia. However, generally not used orally as a hypnotic because several hours are required to achieve maximal effectsa and barbiturates have decreased effectiveness for sleep induction and maintenance after 2 weeks. |
|||
Primary | LUMINAL Approved UseRelief of anxiety, tension, and apprehension. However, barbiturates used infrequently for routine sedation, since there are few clinical situations in which oral barbiturates provide a safety or efficacy advantage over nonbarbiturate sedatives/hypnotics. |
|||
Primary | LUMINAL Approved UseManagement of tonic-clonic seizures and partial seizures; used alone (particularly in infants and young children) or, more commonly, in combination with phenytoin or other anticonvulsants. |
|||
Preventing | LUMINAL Approved UsePrevention of febrile seizures in infants and young children. |
|||
Primary | LUMINAL Approved UseSecond-line agent in the termination of status epilepticus; may be useful to prevent seizure recurrence after seizures are initially terminated with other anticonvulsants (e.g., diazepam, phenytoin) or for termination of status epilepticus that does not respond to initial therapy with other anticonvulsants. Usefulness of parenteral phenobarbital in terminating acute seizure episodes is limited by its slow onset of action |
|||
Preventing | LUMINAL Approved UseProphylactic management of epilepsy. |
|||
Primary | LUMINAL Approved UsePrevention and treatment of hyperbilirubinemia in neonates |
|||
Primary | LUMINAL Approved UseHas been used to reduce bilirubin concentrations in patients with congenital nonhemolytic unconjugated hyperbilirubinemia or chronic intrahepatic cholestasis. Has been used in the management of hyperlipemia associated with intrahepatic and extrahepatic cholestasis |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/monograph/phenobarbital.html
Phenobarbital is administered orally or by IM or slow IV injection. For treatment of anxiety, phenobarbital is administered orally 6 mg/kg daily or 180 mg/m2 daily, in 3 equally divided doses. For treatment of seizure disorders, the drug is administered orally 15–50 mg 2 or 3 times daily. Alternatively, 3–5 mg/kg or 125 mg/m2 daily; IV or IM 4–6 mg/kg daily for 7–10 days to reach therapeutic blood concentrations; alternatively, 10–15 mg/kg daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16981722
Potentiation of the GABAA by phenobarbital was evaluated in HEK293 cells expressing recombinant rat GABAA receptors. Currents were recorded using the cell-flow technique and corrected for receptor desensitization. Co-application of phenobarbital with 300uM GABA lead to 20-30 amplification of chloride currents with EC50 of 100-200 uM
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
768420
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
725419
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
725819
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
||
|
NCI_THESAURUS |
C67084
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
633118
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT001491
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL40
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
SW9M9BB5K3
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
12598276
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
100000091098
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
DTXSID0021123
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
4172
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
200-322-3
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
SW9M9BB5K3
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
82077
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | RxNorm | ||
|
C76956
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
SUB09771MIG
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
PHENOBARBITAL SODIUM
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | Description: White, crystalline granules or a white, crystalline powder; odourless. Solubility: Freely soluble in water; soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Hypnotic; sedative; anticonvulsant. Storage: Phenobarbital sodium should be kept in a tightly closed container, protected from light. Additional information: Phenobarbital sodium is hygroscopic. Even in the absence of light, Phenobarbital sodium is graduallydegraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Phenobarbital sodium contains not less than 98.0% and not more than 101.0% of C12H11N2NaO3, calculated withreference to the dried substance. | ||
|
m8622
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
57-30-7
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY | |||
|
8070
Created by
admin on Fri Dec 15 14:59:52 GMT 2023 , Edited by admin on Fri Dec 15 14:59:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD